Bordetella pertussis is the causative agent of whooping cough or pertussis, a respiratory disease that is most severe in infants and young children. Although vaccination has significantly re duced morbidity and mortality, pertussis remains an endemic disease and is one of the major causes of vaccine-preventable deaths today, with WHO estimates of 45 million cases and 409,000 deaths each year. In recent years a resurgence of pertussis was observed in a number of vaccinated populations (6, 29) . Furthermore, it has become increasingly clear that pertussis is not only a childhood disease but also is highly prevalent among adults (21) . This has called into question the level of protection provided by current pertussis vaccines and highlighted the need for a better understanding of the molec ular mechanisms underlying the pathogenesis of B. pertussis infection.
Bacteria produce a complex array of virulence factors, in cluding toxins and adhesins, which facilitate colonization and/or suppress immune responses and allow the bacteria to establish infection in the host. One of these virulence factors, the type III secretion system (TTSS), is a specialized secretory apparatus that allows gram-negative bacteria to inject proteins, known as effectors, directly into the eukaryotic cell cytosol. In laboratory conditions bacteria can be induced to secrete TTSS substrates, which include effectors and proteins involved in the delivery process, into the extracellular milieu in the absence of eukaryotic cells. TTSSs have been shown to be important me diators of virulence of a range of animal pathogens, including Yersinia spp., Salmonella spp., Shigella spp., Escherichia coli, andBordetella bronchiseptica (15, 39) . Yuk and colleagues have reported that the TTSS of B. bronchiseptica modulates den dritic cell (DC) maturation (31, 33) , enhancing production of the anti-inflammatory cytokine interleukin-10 (IL-10) and pro moting bacterial persistence (32) .
Despite reports describing transcription of genes encoding components of the Bordetella bsc TTSS machinery in B. per tussis Tohama I (14, 22) , the B. pertussis isolate chosen for genome sequencing, studies to date have failed to demonstrate TTSS effector secretion by B. pertussis in vitro or in vivo (9, 22) . The sequencing of the B. pertussis Tohama I genome has re vealed an extraordinary high level of genetic flexibility (28) , and this raises concerns about the adequacy of laboratoryadapted strains for the study of natural clinical pathogenesis. Differences in gene expression have been shown to affect vir ulence characteristics of laboratory-adapted versus corre sponding low-passage clinical isolates of E. coli, Staphylococcus aureus, and Pseudomonas aeruginosa (11, 34, 37) .
Here we demonstrate secretion of the Bordetella TTSS ef fector, Bsp22, by a significant portion of low-passage clinical isolates of B. pertussis, but not by common laboratory-adapted strains, such as Tohama I and Wellcome 28. Mutation of bscN, which encodes an essential component for TTSS secretion across bacterial membranes, abolished in vitro secretion of TTSS substrates by a clinical isolate of B. pertussis, resulting in a reduced ability of the bacteria to colonize the respiratory tracts of mice, and this was associated with enhanced local inflammatory and antigen-specific cellular and humoral im mune responses. Our data suggest that expression of a func tional TTSS is a feature of natural infection of humans with B.
Protein identification by MALDI-TOF mass spectrometry and immunoblot
ting. For matrix-assisted laser desorption-ionization-time of flight (MALDI-TOF) mass spectrometry analysis of protein samples, culture supernatants were harvested from Bordetella spp. following 24 h of growth in liquid culture. Filtered supernatants were precipitated with 30% ammonium chloride. Protein pellets were analyzed by MALDI-TOF mass spectrometry, and identified peptide frag ments were searched against the predicted proteins from the complete B. bron chiseptica RB50 and B. pertussis Tohama I genomes (www.sanger.ac.uk/Projects /B_pertussis/). For Western blots, cultures were harvested for each bacterial strain at the same stage of bacterial growth, as determined by measurements of optical density at 600 nm (OD600), and total protein from a 1-ml supernatant fraction was precipitated with 10% (wt/vol) trichloroacetic acid and resuspended in sample buffer. Proteins were separated on 10% (wt/vol) sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels and transferred to nitrocellulose membranes (Sigma) prior to Western blotting with a polyclonal Ab raised against B. pertussis Bsp22, pertussis toxin (PT), or filamentous hemagglutinin (FHA), followed by the appropriate secondary Ab.
In vitro growth curves. B. pertussis 12743 and NbscN B. pertussis 12743 were grown in SS medium in 100-ml cultures inoculated at a starting OD600 of 0.2. Samples (1 ml) were removed at 4, 8, 12, 23, 27, 37 , and 49 h, OD600 was determined, and CFU counts were performed by plating neat and diluted sam ples on BG agar plates.
In vitro cytotoxicity and adherence assays. DC were expanded in vitro from bone marrow of BALB/c mice by culture for 10 days with granulocyte-macrophage colony-stimulating factor as described previously (13) . Murine DC, 1774 macrophages, and human HEK-293T epithelial cells (1 X 106/ml) were incu bated in Dulbecco's modified Eagle's medium supplemented with 8% fetal calf serum in 24-well plates. Stationary-phase cultures of Bordetella spp. were har vested, resuspended in 1% casein, and added to triplicate wells at a multiplicity of infection (MOI) of 20,100, or 500. Cytotoxicity was determined after 4 h using the Cytotox 96 nonradioactive cytotoxicity assay (Promega), which measures lactate dehydrogenase release as a measure of cell lysis. For detection of bacte rial adherence to macrophages and of internalization, 1774 cells were incubated with Bordetella spp. at an MOI of 100. Following incubation at 37°C for 2 h, the contents of each well were harvested, washed to remove unbound bacteria, and resuspended in either 1 ml of medium supplemented with kanamycin (100 pg/ml) to kill extracellular bacteria or 1 ml medium alone. The cell suspensions were incubated at 37°C for a further 1 h and then centrifuged at 1,200 rpm for 5 min. The cells were washed and resuspended in 1 ml phosphate-buffered saline with 1% (wt/vol) Triton X-'lOO and left at room temperature for 5 min. One hundred-microliter samples of the appropriate dilutions of the lysed cells were then plated in triplicate onto BG agar plates and incubated at 37°C for 2 days for B. bronchiseptica and 3 to 5 days for B. pertussis.
B. pertussis infection of mice. Mice were infected with WT or NbscNB. pertussis 12743 by exposure to an aerosol of bacteria for 15 min as described previously (20) . The standard inoculum was 2 X IO10 bacteria/ml (based on OD600), and this was reduced or increased by two-to threefold to achieve a lower or higher initial colonization. Four mice from each experimental group were sacrificed 3 h and 3, 7, 14, 21, and 28 days after challenge to assess the number of viable bacteria in the lungs. The numbers of CFU in lung homogenates were estimated as de scribed previously (20) . Results are given as the mean numbers of B. pertussis CFU for individual lungs from four mice per experimental group. The sensitivity of the assay was 0.56 log10 CFU per lung.
Quantification of cytokine concentrations and neutrophil infiltration into the
lungs. Lung homogenates were centrifuged at 13,000 rpm for 5 min, and the concentrations of IL-'IO, IL-'12p70, IL-'1£, tumor necrosis factor alpha (TNF-a), macrophage inflammatory protein 1 (MIP-1) and MI P-2 (R&D Systems), IL-12p40, IL-6, and transforming growth factor 3 (BD Pharmingen) were deter mined by enzyme-linked immunosorbent assay (ELISA) according to the man ufacturer's instructions. Neutrophil infiltration into the lungs was quantified by performing differential counts on hematoxylin-and-eosin-stained cytospin prep arations of cells recovered by bronchoalveolar lavage as described previously (23) .
Detection of antigen-specific immune responses. Spleens and serum samples were recovered from mice 14, 21, and 28 days after bacterial challenge. Spleen cells (2 X 106 cells/ml) were stimulated with sonicated B. pertussis, PT, FHA, or medium alone and incubated at 37°C for 72 h. Supernatants were removed, and gamma interferon (IFN-y) and IL-17 concentrations were determined by ELISA. Lung T cells were purified on T-cell isolation columns as described previously (23) . Lung T cells were stimulated with heat-inactivated B. pertussis antigen and splenic antigen-presenting cells (2 X 106 irradiated spleen cells). After 5 days the surviving T cells were stimulated with phorbol myristate acetate and ionomycin for 1 h, and then brefeldin A was added for 4 h at 37°C. Cells were stained with fluorescently labeled Abs specific for CD4 (eBioscinces). Cells were then fixed, permeabilized, and incubated with fluorescently labeled anti-IFN-y or anti-IL-17 Abs (BD Pharmingen) according to the manufacturer's instructions (Fix & Perm cell permeabilization kit; Invitrogen). Immunofluorescence was Vol.. 76, 2008 BORDETELLA PERTUSSIS TYPE III SECRETION SYSTEM 1259 analyzed using Summit software on a Cyan ADP flow cytometer (Dako). Anti-5. pertussis immunoglobulin G (IgG), IgG2a, and IgG'l Ab titers were determined by ELISA as described previously (13) . Results are expressed as log10 end point Ab titers, determined by extrapolation of the straight part of the dilution curve, versus the OD492 value of the control serum for naive mice. Statistical analysis. Statistical analysis was performed using Graphpad Prism. Student's t test was used to compare the mean values between two groups. Statistical differences in mean values between more than two experimental groups were determined by analysis of variance. Linear regression was used to examine the correlation between bacterial growth estimated by CFU counts and OD600. A nonlinear regression analysis was performed on the growth curves for B. pertussis 12743 and SbscN B. pertussis 12743. An Akaike's information crite rion test with a confidence interval of 95% was applied to the data, with a supplemental t test, to determine if the growth curves of bacterial strains are different.
RESULTS

Secretion of TTSS effector proteins by clinical but not laboratory-adapted isolates of B. pertussis. B. pertussis
Tohama I is well characterized and was chosen for genome sequencing (28) but has been through extensive laboratory passage since its isola tion in Japan in 1954 (16) . Since the TTSS expression and secre tory function of Yersinia is regulated and activated in vivo by eukaryotic cell contact and can be altered by prolonged labora tory passage (4,36), we examined low-passage B. pertussis isolates from the ATCC (B. pertussis 12743, 12742, and 9340) and com pared these with the laboratory-adapted strains (Tohama I and Wellcome 28) for expression of Bsp22. Bsp22, whose gene is located in the TTSS operon in B. pertussis and B. bronchiseptica (www.sanger.ac.uk/Projects/Bjaertussis/), is secreted by B. bron chiseptica (39) and is a useful marker of TTSS secretory function. In the present study, His-tagged Bsp22 was cloned and expressed in E. coli and the purified protein was used to generate polyclonal anti-Bsp22 Abs. Western blotting with anti-Bsp22 revealed signif icant quantities of secreted Bsp22 protein in culture supernatants of B. pertussis 12743 and 9340, but not in 12742, Tohama I, or Wellcome 28 (Fig. 1A) . These data demonstrate that two of the three early isolates from the ATCC that were examined expressed TTSS proteins in vitro, but this may have been lost in the common laboratory-adapted strains Tohama I and Wellcome 28.
We next examined supernatants from stationary-phase cul tures of 16 clinical isolates, cultivated from infants or adults with whooping cough in The Netherlands between 1949 and 2005. Western blotting with anti-Bsp22 Abs revealed secretion of Bsp22 in 15 of 16 isolates ( Fig. 1 ; results are shown for 8 clinical isolates; an additional 8 [not shown] all expressed Bsp22). Bsp22 was also detected in B. bronchiseptica RB50 but not /I pertussis Tohama I or Wellcome 28. PT was detected in all strains except B. bronchiseptica RB50, confirming that the clinical isolates were B. pertussis and not B. bronchiseptica. These results demonstrate that a large proportion of the lowpassage clinical isolates of B. pertussis examined have a func tional TTSS.
In order to confirm these findings and to facilitate identifi cation of additional Bordetella TTSS substrates, we carried out mass spectroscopy analysis on total secreted proteins from culture supernatants. MALDI-TOF analysis revealed a num ber of known Bordetella virulence factors, including Mutation of bscN abolishes expression of TTSS effector pro teins by B. pertussis 12743 but does not affect bacterial growth in vitro. In order to assess the contribution of the TTSS to the virulence of BP 12743, we constructed a strain carrying an insertional mutation of the bscN gene. Mutation of bscN in B. bronchiseptica or its homologs, yscN in Yersinia and invC in Salmonella, has been shown to abolish in vitro TTSS secretion and in vivo TTSS-mediated effects on host cells (7, 38^-0). For comparative purposes, we also mutated bscN in B. bronchisep tica RB50. Bsp22 protein was detected by Western blotting in the culture supernatants of WT B. pertussis 12743 and B. bron chiseptica RB50 but not in MiscN derivatives (Fig. 2 ). Further- more, Bsp22, BopN, and BopD were detected by mass spec trometry analyses of secreted proteins of WT but not AbscN derivatives ( Table 1 ). Mutation of bscN did not affect secretion of other virulence factors, including FHA, adenylate cyclase toxin, and pertactin ( Table 1 and Fig. 2 ). These results dem onstrate that mutation of the bscN gene abolishes secretion of TTSS substrates by B. pertussis 12743 and B. bronchiseptica RB50 and demonstrate that BscN is an essential component of the B. pertussis TTSS. Furthermore, mutation of bscN did not significantly affect bacterial growth rate. The in vitro growth curves based on ODf)00 ( Fig. 3A) and CFU (Fig. 3B ) were almost superimposable for B. pertussis 12743 and AbscN B. pertussis 12743. Nonlinear regression analysis with Akaike's information criterion test determined that there was a 93% probability that the curves for the two bacterial strains were identical. Furthermore linear regression analysis demonstrated a highly significant (P < 0.001) correlation between ODf)00 and CFU for B. pertussis 12743 and AbscN B. pertussis 12743. These findings demonstrate that OD600 can be used as an accurate estimate of the number of viable bacteria and suggest that equivalent numbers of viable WT and TTSS mutant bacteria were employed for experiments to compare the virulence levels of and immune responses to B. pertussis 12743 and AbscN B. pertussis 12743 in vitro and in vivo. The TTSS of/J. pertussis 12743 promotes adherence to macro phages but does not mediate cytotoxicity in vitro. Consistent with previous reports (39, 40) , B. bronchiseptica RB50 was significantly cytotoxic to cultured epithelial cells, macrophages, and DC (Fig. 4A ) and this activity was lost in the AbscN mutant. In contrast, no significant cell lysis was detected in any cell type incubated with WT or AbscN B. pertussis 12743. The TTSS of Yersinia spp. plays a crucial role in preventing bacte rial uptake during infection (4), while the TTSS of Salmonella spp. mediates bacterial uptake to facilitate tissue invasion and intracellular replication (12) . Here we investigated the role of the Bordetella TTSS in bacterial uptake. Significantly higher CFU were detected in kanamycin-treated macrophages cul tured with AbscN B. bronchiseptica than in those cultured with WT B. bronchiseptica, indicative of a higher number of inter nalized viable mutant bacteria (Fig. 4B) . After correcting for cell death induced by B. bronschiseptica, there was still signif icantly greater uptake of the mutant than the WT B. bronschi septica (data not shown). In contrast, the numbers of CFU recovered following treatment with medium only were similar following culture with WT or AbscN B. bronchiseptica, suggest ing that the TTSS of B. bronchiseptica did not facilitate binding to the cell surface. The numbers of viable WT and AbscN B. pertussis 12743 CFU recovered from kanamycin-treated macro phages were very similar, indicative of similar numbers of in ternalized B. pertussis CFU. In contrast, the number of viable B. pertussis CFU recovered following treatment with medium alone from cells cultured with AbscN B. pertussis f2743 was significantly lower than the number of WT bacteria, indicating a lower number of cell-associated bacteria following incuba tion with the mutant bacteria (Fig. 4B) . These results demon strate that the TTSS of B. bronchiseptica RB50 inhibits bacte rial uptake by murine macrophages, whereas the TTSS of B. pertussis f2743 promotes adherence of the bacteria to macro phages in vitro. (B) The number of viable bacteria was determined by performing CFU counts after plating on BG agar. (C) CFU counts were plotted against OD600 for each strain separately, and linear regression analysis was performed. The correlation (rvalue) and level of significance (P value) are shown. tory responses in the lungs (13, 24) and adaptive immune responses, mediated by Thl and Thl7 cells, which help to clear bacteria from the respiratory tract (13, 20) . Here, we examined local innate inflammatory cytokine production in the lungs of mice infected with WT and MscN B. pertussis 12743. We de tected significantly higher concentrations of the proinflammatory cytokines, TNF-a (P < 0.01), IL-1[3 (P < 0.01) and IL-6 (P < 0.05), and proinflammatory chemokines MIP-la (P < 0.01 ) and MIP-2 (P < 0.05 ) in the lungs 3 h after challenge with the MscN bacteria compared with WT B. pertussis 12743 (Fig.  5 ). Furthermore, the concentrations of IL-1|3, MI P-1 a, and MIP-2 remained significantly higher in the lungs of mice in fected with the MscN B. pertussis 12743 up to 7 to 14 days postchallenge. We also detected significantly higher concentra tions of IL-12p40 and IL-6 in the lungs of mice 7 days after challenge with MiscN B. pertussis 12743. In contrast, the con centrations of the immunosuppressive cytokine IL-10 were consistently lower in mice infected with MiscNB. pertussis than in those infected with WT bacteria. The concentration of trans forming growth factor |3 in the lungs was not significantly changed over the course of infection with B. pertussis 12743 or MscN B. pertussis 12743 (Fig. 5 ). These results suggest a role for the TTSS of B. pertussis 12743 in suppressing innate proin flammatory cytokine and chemokine responses in the lungs, especially early in infection.
Enhanced innate and adaptive immune responses in mice infected with
Analysis of the cellular content of bronchoalveolar lavage samples 7 days postchallenge revealed a nonsignificant in crease in the number of neutrophils in the lungs of mice in fected with MscN B. pertussis 12743 ( 4.6 x 104 ± 1.5 x 104/lung) compared with that in lungs of mice infected with B. pertussis 12743 ( 2.6 x 104 ± 1.5 x 104/lung). However, histo logical analysis of lungs did not reveal evidence of increased pathology in the lungs of mice infected with the mutant versus WT bacteria (data not shown).
We examined antigen-specific cytokine production in mice infected with WT or MscN B. pertussis 12743 by stimulation of spleen cells with B. pertussis sonicate, purified PT, or FHA. We detected B. pertussis-specific IL-17 and Il N-y production by spleen cells recovered 14 or 21 days after infection of mice with WTB. pertussis 12743 ( Fig. 6 ). However, antigen-specific IL-17 and Il N-y production was significantly stronger in mice in fected with MscN B. pertussis T21A3. The enhanced IL-17 production in mice infected with the mutant bacteria in re sponse to PT and also to B. pertussis sonicate was particularly striking, and this was a consistent finding at days 14, 21 (Fig. 6 ), and 28 (data not shown) postchallenge. Preliminary experi ments to determine the frequency of antigen-specific T cells in the lungs of infected mice (based on a single time point, day 14 postchallenge) revealed a higher frequency of B. pertussis-spe cific Thl and Thl7 cells in mice infected with MscN B. per tussis 12743 (IFN-y secreting, 2.86%; IL-17 secreting, 1.98%) than in mice infected with the WT bacteria (IFN-y secreting, 1.92%; IL-17 secreting, 0.88%). Collectively, these results sug gest that the TTSS may suppress antigen-specific IFN-y and IL-17 production during infection of mice with B. pertussis 12743. Significantly higher B. pertussis-specific serum IgG lev els in mice infected with MscNB. pertussis 12743 than in mice infected with WT bacteria were also observed ( Fig. 7) . Con sistent with the stronger Thl responses, we detected signifi cantly higher titers of serum IgG2a in mice infected with MscN B. pertussis 12743 (Fig. 7) . In contrast, there were no differ ences in serum IgGl between the mutant and WT bacteria. These results suggest that the Bordetella TTSS may suppress Ab responses, especially IgG2a, as a consequence of suppress ing the induction of Thl cells.
The TTSS of B. pertussis 12743 enhances bacterial persis tence in the lungs of mice. In order to examine the role of a functional TTSS in virulence of Bordetella in vivo, BALB/c mice were infected by exposure to an aerosol containing equiv alent concentrations (2 x 10lo/ml) of either WT or MscN B. pertussis 12743. After an initial rise in bacterial numbers, peak ing at day 7, WT B. pertussis 12743 began to be steadily cleared from the lungs between days 7 and 21, with complete clearance of the bacteria 28 days postinfection (Fig. 8A) . In contrast, MscN B. pertussis 12743 colonized the lungs to a significantly lower degree at each time point examined and began to be cleared from the lung earlier in infection and was completely bronchiseptica RB50 (B) or B. pertussis 12743 (C) at an MOI of 100:1. Adherence was assessed by assessing CFU counts following 2 h of incubation followed by 1 h of treatment with kanamycin or medium only. *, P < 0.05; **, P < 0.01 (AbscN versus WT). Results are representative of three experiments. cleared by day 21. The lower number of mutant bacteria re covered 3 h after challenge was a consistent finding in three experiments using our standard challenge inoculum. Evidence from over 100 challenge experiments with B. pertussis has shown that this method of infection results in highly reproduc ible lung colonization of mice within an experiment. Further more, we have also shown a highly significant correlation be tween protection in this model and vaccine efficacy in children (26) . We used OD600 to estimate the number of bacteria in the challenge inoculum, and, since there was a highly significant correlation between OD600 and CFU counts (Fig. 3) , it is unlikely that the difference in colonization at 3 h reflects ex posure to a lower number of viable bacteria. Furthermore, the in vitro growth curves, as determined by measuring either OD600 or CFU, for the TTSS mutant and WT bacteria were almost identical (Fig. 3) . Nevertheless, in order to provide further evidence of the impact of the TTSS on virulence in vivo, we examined the course of infection when differing con centrations of the challenge inocula resulted in higher or lower initial lung colonization. In a challenge experiment where the initial colonization was 3.8 log10 CFU per lung for the WT B. pertussis, ¿sbscN B. pertussis 12743 was cleared within 7 days and there were significantly greater numbers of CFU recov ered at 3, 7, and 14 days postchallenge from the lungs of mice infected with the WT bacteria than with mutant bacteria (Fig.  8B) . In contrast, when the initial colonization was 4.8 log10 CFU per lung for the WT B. pertussis, the effect of the muta tion was less obvious. Although CFU recovered from the mice infected with the TTSS mutant were 4-to 10-fold (0.6 to 1 log10) lower than CFU of WT B. pertussis on days 3 and 7, these differences were not statistically significant (Fig. 8C ). The absence of the TTSS and the corresponding loss of its cell binding and immunosuppressive effects may be less obvious when the lungs are overwhelmed with a high number of bac teria in the aerosol. Nevertheless the dramatically reduced CFU recovered from mice infected with the TTSS mutant in mice with lower initial colonization (which may be more rele vant to the mode of exposure in humans) suggests that the TTSS does play an important role both in colonization and persistence of B. pertussis 12743 in the lungs following aerosol challenge of mice. Despite the lower bacterial load, we de tected significantly higher concentrations of innate proinflammatory cytokine (Fig. 5 ) and antigen-specific Thl and Thl7 cells (Fig. 6 ) in mice infected with the mutant than in mice infected with WT B. pertussis (the experiments shown in Fig. 5 to 7 correspond to a level of bacterial colonization shown in Fig. 8A ). This provides indirect evidence that the lower lung colonization observed with the mutant bacteria is unlikely to be due to exposure to a lower dose of viable bacteria but may reflect reduced adherence and a stronger host immune re sponse due to the absence of the immune-subversive proper ties of the TTSS.
DISCUSSION
This study has demonstrated for the first time that B. per tussis expresses a functionally active TTSS, which may be lost following prolonged in vitro culture of the bacteria. We have identified several substrates of the B. pertussis TTSS and shown that the TTSS of B. pertussis is an important virulence factor and immunomodulatory apparatus for subverting protective immune responses and prolonging survival in the host. It ap pears that the TTSS may facilitate colonization and survival of B. pertussis by promoting bacterial adherence and by inhibiting local innate inflammatory responses and the consequent induc tion of antigen-specific Thl, Thl7, and Ab responses that func tion to clear the bacteria from the respiratory tract. The closely related pathogens B. pertussis and B. bronchisep tica produce a range of common virulence factors, including adhesins and toxins, which function to establish and maintain the infection, but have also evolved distinct strategies for sur vival in the host. The relatively short-lived and acute severity of B. pertussis infection of humans, which favors a high rate of host-to-host transmission, contrasts with the relatively asymp tomatic and often lifelong persistence of B. bronchiseptica in fection in animals. This was thought to be consistent with the functional activity of the TTSS in B. bronchiseptica, which sup presses DC maturation and migration (32, 33) , and the lack of TTSS function in B. pertussis Tohama I. However, the present study has revealed that clinical isolates of B. pertussis do ex-press a functionally active TTSS, which plays a role in promot ing more efficient bacterial colonization and persistence through immunosuppression following respiratory infection of mice. We demonstrated significant secretion of Bsp22, a reli able marker of a functional TTSS in Bordetella spp. (39) , by 15 of 16 clinical isolates of B. pertussis, in addition to 2 isolates obtained from the ATCC, B. pertussis 12743 and 9340, which had not undergone extensive laboratory passage. We also dem onstrated secretion of two additional Bordetella TTSS sub strates, BopN and BopD, by B. pertussis 12743. In contrast, secretion of TTSS substrates could not be detected in two well-studied laboratory-adapted strains of B. pertussis, Tohama I and Wellcome 28. While the TTSS loci are conserved and have been shown to be transcribed in B. pertussis Tohama I during in vitro growth, it has been suggested that protein trans lation is prevented by a posttranscriptional block (22) . The sequencing of the B. pertussis Tohama I genome revealed ex tensive expansion of the insertion sequence element IS-ZA7, indicative of large-scale genome rearrangements and thus a high level of genome plasticity. Long-term laboratory passage Infect. Immun. can lead to significant changes in gene expression and viru lence factor production in E. coli and Pseudomonas and Staph ylococcus spp. (11) . Compared with that in laboratory-cultured strains, transcription of genes encoding the TTSS and its ef fector proteins was upregulated in a highly adherent P. aerugi nosa strain isolated from the lung of a cystic fibrosis patient, and this correlated with increased cytotoxicity in vitro and enhanced virulence in the respiratory tracts of mice (37) . Fur thermore, it has been reported that the Yersinia YopT TTSS effector protein is not expressed by serotype 03 strains of Y. pseudotuberculosis that have been extensively passaged in vitro (36) . Significant changes in gene transcription by clinical iso lates of B. pertussis were reported after as few as 12 laboratory passages (2), indicating that B. pertussis, like other bacterial species, can alter gene expression when introduced into a new environment. It is therefore possible that the absence of a functional TTSS in B. pertussis Tohama I and Wellcome 28 is a consequence of long-term laboratory culture in the absence of eukaryotic cell contact.
The present study demonstrated that the TTSS of B. bronchiseptica may facilitate bacterial persistence through subver sion of bacterial uptake by macrophages, a strategy in the pathogenesis of Yersinia spp. (5) . We found that B. pertussis 12743 did not induce cytotoxicity in macrophages, DC, and epithelial cells. However, consistent with previous reports (39, 40) , B. bronchiseptica was cytotoxic to a range of cultured cells. Although other TTSS effector proteins may also contribute to cytotoxicity, it has been demonstrated that BteA, also called BopC, is required for the induction of necrotic cell death (19, 27) . Interestingly, BteA/BopC was not detected in secreted proteins from B. pertussis 12743. In contrast, we found evi dence that the TTSS of B. pertussis facilitates bacterial binding to macrophages in vitro. In addition, compared with the WT bacteria, the TTSS mutant of B. pertussis YE1Y3 had signifi cantly reduced colonization in the lungs 3 h after respiratory challenge of mice. Taken together, these data suggest that the TTSS of B. pertussis may function as a host adherence factor, as has been demonstrated for enteropathogenic E. coli (17) .
Significantly, we found evidence that the TTSS facilitates persistence of the bacteria in the respiratory tract by subverting innate and adaptive immune responses. Protective immunity to B. pertussis is mediated through recruitment of neutrophils and macrophages to the lungs, local secretion of inflammatory cy tokines, and the induction of B. pertussis-specific Thl cells, Thl7 cells, and Ab responses (18, 20, 24) . IL-12-induced IFN-y production by NK cells and Thl cells prevents bacterial dis semination from the respiratory tract and activates production of opsonizing and complement-fixing IgG2a Abs in the mouse (3, 20) . IL-23, IL-1, TNF-a, and IL-6 promote the differenti ation and expansion of Thl7 cells, and these cells have been implicated in inflammatory responses that mediate autoimmu- , or high (C) initial colonization with the WT B. pertussis. Groups of four mice were sacrificed 3 h and 3, 7, 14, 21, and 28 days later, and CFU counts were performed on lung ho mogenates. The dashed line represents the limit of detection. **, P < 0.01; ***,P < 0.001 (STs/'N versus WT). Results are representative of three experiments for panel A and one experiment each for panels B and C. nity and also function in the recruitment of neutrophils to the site of infection, where they may help contain the pathogen until a subsequent clearing IFN-y-producing Thl response can be generated (25, 35) . We have recently reported that Thl7 cells have a protective role in vaccine-induced immunity to B. pertussis by activating bacterial killing by macrophages (13) . In the present study we found evidence that deletion of a func tional TTSS from B. pertussis 12743 resulted in enhancement of local inflammatory responses in the lungs of infected mice. Despite the lower bacterial burden in the lungs, mice infected with the TTSS mutant had significantly greater local IL-1(3, IL-12p40, MI P-1 a, and MIP-2 production. We also observed a modest reduction in IL-10 in mice infected with the TTSS mutant, and this was significant at day 14. This is consistent with the report on B. bronchiseptica where antigen-specific IL-10 production in mice infected with the TTSS mutant is lower than that in mice infected with WT bacteria (32) . In contrast, we demonstrated significantly greater B. pertussis specific IFN-y, IL-17, and IgG2a responses of mice infected with the TTSS mutant than with WT B. pertussis 14 to 28 days after B. pertussis challenge. The augmentation of the IL-17 response to PT in mice infected with the mutant bacteria was particularly striking. Although we do not know the precise mechanisms, this may reflect enhancement of innate IL-1, which together with IL-23 is known to promote the differen tiation of Thl7 cells (13) . The enhanced cellular immune re sponse in mice infected with the TTSS mutant correlated with earlier respiratory clearance of TTSS-defective bacteria than of WT bacteria. Thus, it appears that the TTSS contributes to persistence of B. pertussis by suppressing innate inflammatory responses, which not only allows greater bacterial colonization, but also delays clearance due to significant suppression of Thl, Thl 7 , and Ab responses.
Our study provides the first evidence that B. pertussis uses the TTSS as a means of colonization and survival in the host and may in particular target the innate immune system. Fur thermore, we have demonstrated that one of the substrates, Bsp22, is secreted in significant quantities by clinical isolates of B. pertussis and is immunogenic in animals.
